1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Product Pipelines
4. TECHNOLOGICAL OUTLOOK
5. HYPERURICEMIA TREATMENT MARKET BY DISEASE TYPE
5.1. Introduction
5.2. Gout
5.3. Chronic Kidney
5.4. Others
6. HYPERURICEMIA TREATMENT MARKET BY TREATMENT
6.1. Introduction
6.2. Uricosuric Agents
6.3. Xanthine Oxidase Inhibitors
6.4. Recombinant Uricases
6.5. Non-Pharmacological Interventions
6.6. Others
7. HYPERURICEMIA TREATMENT MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others
8. HYPERURICEMIA TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Thailand
8.6.6. Indonesia
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Amgen. Inc
10.2. Atom Therapeutics Co., Ltd
10.3. Shanton Pharma Co., Ltd.
10.4. AstraZeneca PLC
10.5. Teijin Pharma Limited
10.6. Hikma Pharmaceuticals PLC
10.7. Pfizer Inc
10.8. Ironwood Pharmaceuticals
10.9. Takeda Pharmaceutical Company Limited
10.10. Eisai Co., Ltd.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES